PLGA microsphere-based composite hydrogel for dual delivery of ciprofloxacin and ginsenoside Rh2 to treat Staphylococcus aureus-induced skin infections

Drug Deliv. 2020 Dec;27(1):632-641. doi: 10.1080/10717544.2020.1756985.

Abstract

When antibiotic-resistant pathogenic bacteria pose a high threat to human health, bacterial multidrug efflux pumps become major contributors to the high-level antibiotic resistance in most microorganisms. Since traditional antibiotics are still indispensable currently, we report a dual drug delivery system to maximize the antibacterial efficacy of antibiotics by inhibiting efflux pumps in bacteria before their exposure to antibiotics. In this research, a microsphere/hydrogel composite was constructed from ciprofloxacin (Cip)-loaded poly (lactic-co-glycolic acid) (PLGA) microspheres and ginsenoside Rh2 (G-Rh2) dispersed thermo-sensitive hydrogel to treat skin infections. In vitro drug release studies indicated that while G-Rh2 in hydrogel presented a faster and short-term release manner to rapidly inhibit the NorA efflux pumps, Cip showed a sustained and long-term release behavior to provide a local high concentration gradient for facilitating drug percutaneous penetration. The combination of Cip and G-Rh2 demonstrated a high degree of synergism against both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), hence significantly improving their in vitro antibacterial activity and efficiency. Moreover, the antibacterial performance of the microsphere/hydrogel composite with a sequential release profile is superior to that of other formulations in mouse model of MRSA skin infections, indicating its great potential to treat antibiotic-resistant skin infections.

Keywords: Ciprofloxacin; ginsenoside Rh2; microsphere/hydrogel composite; sequential release; skin infections.

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Ciprofloxacin / administration & dosage*
  • Ciprofloxacin / pharmacokinetics
  • Ciprofloxacin / pharmacology
  • Drug Delivery Systems
  • Drug Liberation
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Drug Synergism
  • Drug Therapy, Combination
  • Ginsenosides / administration & dosage*
  • Ginsenosides / pharmacokinetics
  • Ginsenosides / pharmacology
  • HaCaT Cells
  • Humans
  • Hydrogels* / chemistry
  • Hydrogels* / pharmacokinetics
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Mice
  • Microspheres
  • Polylactic Acid-Polyglycolic Acid Copolymer* / administration & dosage
  • Polylactic Acid-Polyglycolic Acid Copolymer* / pharmacokinetics
  • Staphylococcal Skin Infections / drug therapy*
  • Staphylococcus aureus / drug effects*

Substances

  • Anti-Bacterial Agents
  • Ginsenosides
  • Hydrogels
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Ciprofloxacin
  • ginsenoside Rh2

Grants and funding

This research was funded by the National Natural Science Foundation of China [No. 81773660, 81803467] and the Natural Science Fund Project of Guangdong Province [2016A030312013].